Hpgc Renmintongtai Pharmaceutical Corporation’s Net Profit Rose 25.7% in First Three Quarters of 2023

Hpgc Renmintongtai Pharmaceutical Corporation (哈药集团人民同泰医药股份有限公司) (600829.SH) reported a net profit of 240.6 million yuan in the first three quarters of 2023, up 25.7% year-on-year.

Meanwhile, the company posted 7.8 billion yuan in revenue, up 7.8% year-on-year.

At the end of the reporting period, it had 7.3 billion yuan in total assets and 4.6 billion yuan in total liabilities, with a liability-to-asset ratio of 62.8%.